In a phase I open-label study targeting B-cell acute lymphoblastic leukemia, CRISPR/Cas9 technology was used to construct universal CD19/CD22 dual-targeted CAR T cells. This evidence concerns the gene CD22 and B-cell acute lymphoblastic leukemia.